Lung Cancer

Chicago, IL—Alectinib (Alecensa), a next-generation anaplastic lymphoma kinase (ALK) inhibitor, was called a new standard of care for patients with ALK mutation–positive non–small-cell lung cancer (NSCLC), based on results of the phase 3 ALEX clinical trial, which were presented at the 2017 ASCO annual meeting.

Chicago, IL—Osimertinib (Tagrisso) extends progression-free survival (PFS) compared with standard chemotherapy in patients with EGFR T790M mutation–positive non–small-cell lung cancer (NSCLC) who have central nervous system (CNS) metastases, reported Marina C. Garassino, MD, Thoracic Oncology Unit, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, at the 2017 ASCO annual meeting.
Dacomitinib is an irreversible EGFR tyrosine kinase inhibitor that inhibits 3 members of the ErbB protein family—EGFR/HER1, HER2, and HER4—implying that dacomitinib induces a more potent inhibition of EGFR.
The role of nurse navigators has grown exponentially in recent years, and is now regarded as an integral element of oncology treatment and patient care. The Academy of Oncology Nurse & Patient Navigators (AONN+) defines patient navigation as the “process whereby a patient is given individualized support across the continuum of care, beginning with community outreach to raise awareness and perform cancer screening, through the diagnosis and treatment process, and on to short- and long-term survivorship or end of life.” At the Best Practices in Lung Cancer Navigation Summit, held October 22, 2016, in Rosemont, IL, oncology nurse navigators involved in the care of patients with lung cancer convened to discuss the complexities and role of nurse navigators in the treatment of lung cancer.
Immune-related toxicities in patients with NSCLC can be traced back to the mechanism of action of immune checkpoint inhibitors.
When added to treatment with docetaxel, the investigational drug plinabulin improved overall survival by 4.7 months in patients with advanced non–small-cell lung cancer with measurable lesions.
Durability of benefit (ie, the possibility for sustained remission in patients with previously incurable disease) is already one of the hallmarks of immunotherapy. According to a recent statistical analysis, however, this durability even exceeded expectations.
Toxicities related to immunotherapies approved for the treatment of patients with non–small-cell lung cancer (NSCLC) are uncommon but can be life-threatening.
It is now widely known that light cigarettes are no safer than regular cigarettes and were only marketed in an attempt to undermine smokers’ wishes to quit smoking. According to Charlotta Pisinger, PhD, MPH, the tobacco industry is now using the same tactic with electronic cigarettes (e-cigarettes).
Targeted agents and immunotherapy are displacing chemotherapy in certain subgroups of the treatment of lung cancer, but chemotherapy remains a key therapeutic pillar in the daily management of patients with this disease, according to Jean-Charles Soria, MD, PhD, Head of the Drug Development Department, Gustave Roussy, Villejuif, France.
Page 1 of 5
Results 1 - 10 of 48